^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
CancerDetect™

Company:
Viome
Type:
Laboratory Developed Test
Evidence

News

2ms
Viome is partnering with Henry Schein to provide better access to Oral Health Pro™ with CancerDetect™ (PRNewswire)
"Viome...is partnering with Henry Schein to provide better access to Viome's Oral Health Pro™ With CancerDetect™. Viome's laboratory-developed test helps detect early biomarkers of oral and throat cancers, enhancing practitioners' ability to effectively harness the power of preventive care and improve patient outcomes."
Licensing / partnership
|
CancerDetect™
10ms
Detecting salivary host and microbiome RNA signature for aiding diagnosis of oral and throat cancer. (PubMed, Oral Oncol)
CDOT is a non-invasive test that can be easily administered in dentist offices, primary care centres and specialised cancer clinics for early detection of OPSCC and OSCC. This test, having received FDA's breakthrough designation for accelerated review, has the potential to enable early diagnosis, saving lives and significantly reducing healthcare expenditure.
Journal
|
CancerDetect™
almost2years
Viome Life Sciences unveils CancerDetect™, the future of oral and throat cancer detection (PRNewswire)
"Viome Life Sciences, a mission-driven biotechnology company, announces the arrival of its CancerDetect™ test for oral & throat cancer, the first to launch in a series of diagnostic tests in development. This test is the first to detect biomarkers for early-stage oral and throat cancers based on technology that has received FDA Breakthrough Device Designation. CancerDetect™ is available to individuals at higher risk of developing these cancers, fulfilling an unmet need for advanced, earlier detection when it is most easy to treat. Viome's launch of the CancerDetect™ signifies a promising future for saliva-based, early cancer detection testing with Viome's advanced mRNA technology and AI-powered platform."
Launch
|
CancerDetect™